Filter Specialty
Submit To The Journals

Atrial Fibrillation and Dementia

European Journal of Arrhythmia & Electrophysiology. 2020;6(1):Online ahead of journal publication.


There is evidence from multiple trials that atrial fibrillation (AF) is associated with cognitive impairment, cognitive decline and dementia. This is true for vascular dementia as well as Alzheimer’s disease, with both types of dementia sharing important cardiovascular risk factors. Postulated mechanisms for the development of cognitive decline and dementia in patients with AF are multifactorial and include ischaemic stroke, silent stroke secondary to cerebral microinfarcts, cerebral haemorrhage and chronic cerebral hypoperfusion. Based on several observational studies, it can be expected that anticoagulation with vitamin K antagonists as well as direct oral anticoagulants may reduce the risk of cognitive decline and dementia in patients with AF. This, however, needs to be proven by randomised trials. Rhythm control by cardioversion or catheter ablation for AF may also reduce the risk of cognitive decline and dementia significantly according to observational studies. Prospective randomised trials to prove the benefit of rhythm control would require a long follow-up in many thousands of patients, and would therefore be challenging to conduct.


Atrial fibrillation, dementia, cognitive decline, cognitive impairment, vascular dementia, Alzheimer’s disease, anticoagulation, catheter ablation


Norbert Guettler, Kim Rajappan and Edward Nicol have nothing to disclose in relation to this article.

Compliance with Ethics

This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Open Access

This article is freely accessible at © Touch Medical Media 2020


April 19, 2020


28 April 2020

Published Online

June 22, 2020


Norbert Guettler, Air Force Centre of Aerospace Medicine, Strasse der Luftwaffe 322, 82256 Fuerstenfeldbruck, Germany. E:

Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1 AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF during their lifetime.2,3 Irrespective of age, AF incidence also increases with diabetes and hypertension.4 The relationship between AF and cerebrovascular events (such as cerebrovascular accident or stroke and transient ischaemic attack), and the increased risk of developing cognitive impairment and dementia, in these patients are well described.1,5–7 Recent data suggest that AF may be associated with dementia independent of cerebrovascular events. Possible mechanisms include silent cerebral ischaemia caused by cerebral hypoperfusion and cerebral microhaemorrhage.8 Global cerebral hypoperfusion and transient variability in perfusion in the distal cerebral circulation are caused in AF by R-R interval variability and loss of atrial systole. This results in arteriolar hypotension, capillary hypertension and microvascular dysfunction.9 A recent computational study suggests a rate-dependent impact of AF on cerebral haemodynamics. Higher ventricular rates relate to a progressive increase in critical cerebral events (hypoperfusion and hypertensive events) at the distal cerebral circle.10

Vascular dementia and Alzheimer’s disease, the most important degenerative dementia, are the most common types of dementia. On post-mortem findings, Alzheimer’s disease is characterised by neurodegenerative changes in the brain, with amyloid depositions and neurofibrillary tangles. There is increasing evidence that stroke and cardiovascular disease are important risk factors for both vascular dementia and Alzheimer’s disease.11–5 Preclinical findings of cerebrovascular disease, such as increased intima-media thickness of the carotid arteries, white matter lesions and lacunar infarcts in the brain have all been found to be associated with Alzheimer’s disease.16–8 Additionally, conventional vascular risk factors such as hypertension, diabetes mellitus and smoking, have all been noted to be associated with an increased risk of Alzheimer’s disease. Similarities in the underlying pathophysiology of vascular dementia and Alzheimer’s disease suggest that treatment of cardiovascular disease and associated vascular risk factors may potentially prevent or slow the progression of a significant proportion of Alzheimer cases, as no other effective treatment is available.

Study results indicate that AF probably increases the risk of both vascular dementia and Alzheimer’s disease. The relationship to dementia is probably stronger when AF starts in middle age and with a longer duration of AF.19,20 This article outlines the current evidence regarding the relationship between AF and dementia; possible mechanisms of disease; and potential treatment options for AF, that may decrease the risk of, or progression of, cognitive decline and dementia.

Trials investigating the association of atrial fibrillation and dementia

Evidence of the association between AF and dementia is based on prospective and retrospective observational trials, cross-sectional studies, systematic reviews and meta-analyses. A selection of the most important observational studies is summarised in Table 1,13,20–34 with cross-sectional studies in Table 2.19,35–9 For the diagnosis of dementia, Mini-mental State Examination (MMSE) and cognitive tests were performed in most studies.





Several meta-analyses and systematic reviews have investigated the association between AF and dementia. A selection of those is listed in Table 3.40–5 A systematic review of three cross-sectional, two case-control and three prospective studies, conducted by Udompanich et al. in 2013, found an association between cognitive impairment and AF. In the cross-sectional studies, patients with AF had a 1.7-fold to 3.3-fold increased risk of cognitive impairment, and a 2.3-fold increased risk of dementia, compared to patients in sinus rhythm.42 Three meta-analyses with prospective and cross-sectional studies have demonstrated an increased risk of dementia in those with AF, with or without a history of stroke.40,41,43 Individuals with a history of stroke were at greater risk for dementia and cognitive decline and a strong association between AF and dementia was demonstrated in patients under 75 years of age. A more recent meta-analysis of 16 observational studies (almost 2.5 million individuals) demonstrated patients with AF had a greater incidence dementia than those without.44

In another meta-analysis of 11 prospective cohort studies covering 112,876 patients, AF was independently associated with dementia incidence.45 A meta-analysis including five prospective observational studies with a total of 61,008 patients and a median follow-up of 12.5 years also indicates an increased risk of dementia in patients with AF.1 According to this meta-analysis, stroke/transient ischaemic attack-independent contribution of AF to dementia is more impactful than stroke/transient ischaemic attack-dependent effect. The association of AF with cognitive impairment and dementia was also evaluated in a meta-analysis including 21 studies.43 In this cohort, there was a significant association between AF and an increased risk of cognitive impairment independent of a history of stroke. The risk of dementia was also significantly increased.



Thus, there is scientific evidence from very large meta-analyses that suggest AF is an independent risk factor for dementia in patients with normal baseline cognitive function not suffering from acute stroke. Screening for dementia in patients with AF, and including dementia as an independent outcome in large AF trials, is required to confirm this association in prospective and clinical practice.45

Possible mechanisms underlying the association between atrial fibrillation and dementia

It is assumed that AF accelerates neuropathological processes that cause and coexist with dementia, such as the development of Lewy bodies, neurofibrillary tangles and hippocampal sclerosis.46 The mechanisms as to how AF leads to dementia are not fully understood, however it is postulated that the main mechanisms are probably cerebral hypoperfusion caused by beat-to-beat variation in AF, with reduced cardiac output, silent cerebral ischaemia (caused by thromboembolism because of a hypercoagulable state), circulatory stasis, endothelial injury, and up regulation of inflammatory processes.47,48

Cerebral hypoperfusion aggravates white matter change leading to demyelination and axonal damage, and subsequent memory impairment.49,50 Cerebral autoregulation maintains blood circulation even if cardiac output decreases, but may deteriorate in patients with long-term AF.51 Long-term cerebral hypoperfusion induces senile plaque formation and amyloid angiopathy through β– and γ-secretases. These generate and aggregate β-amyloid peptide in the brain, which is thought to be responsible for neuronal death and Alzheimer’s disease.52 Cerebral amyloid angiopathy is mainly caused by amyloid β 42 (Aβ42), with Aβ40 triggering a reduction in blood supply within the brain and driving further Aβ production secondary to dysfunction of the vascular smooth muscle.53 Decreased cerebral blood flow can be measured by single-photon emission tomography (SPECT) with 99mtechnetium-ethyl cysteinate dimer, with potential prognostic value in patients with both AF and dementia.54

Recent data suggest an increased prevalence of cerebral microbleeds in patients with AF, which can also play a role in the pathogenesis of cognitive decline and dementia.2,55 The most vulnerable area for the development of cerebral microbleeds is the hippocampus, which is often affected in patients with Alzheimer’s disease and AF.56

AF is also associated with a proinflammatory state, but the exact relationship between AF-induced systemic inflammation and dementia requires further investigation.2 A proinflammatory state is implicated in the genesis and perpetuation of AF, facilitating thrombus formation and leading to stroke or silent ischaemia. Inflammatory markers identified in patients with AF and dementia include C-reactive protein, interleukin (IL)-2, IL-6, IL-8, and tumour necrosis factor alpha.12 The role of inflammatory and infectious processes serving as links between AF and Alzheimer’s disease has recently been analysed.57

Genetic analysis reveals that AF-related gene PITX2, the gene for the homeobox transcription factor, is significantly associated with dementia. This genetic factor could explain that the relative risk of dementia is paradoxically higher in younger patients with AF.47,48 A study of 37,025 patients without dementia and a follow-up of at least 5 years showed the highest relative risk (RR) of developing Alzheimer’s dementia among those with AF and younger than 70 years of age.13 A higher risk of dementia in younger patients with AF (<67 years of age) was also seen in a study analysing participants of the Rotterdam Study.20 This shows that the association between AF and dementia is not only caused by age-dependent pathological conditions as common risk factors. The currently assumed relationship between AF, cognitive decline and dementia is summarised in Figure 1.



Treatment options for atrial fibrillation decreasing the risk of cognitive decline and dementia

Treatment options for AF are anticoagulation, if indicated, rate control and rhythm control. There is some evidence in the literature that therapeutic options that control rhythm and risk of thromboembolic disease could also have positive effects on cognitive decline and dementia.


Observational trials, such as the Olmsted County population-based study, suggest that anticoagulation of patients with AF with warfarin is associated with reduced cognitive decline.2 However, possible confounders limit confidence in ascribing a cause–effect relationship. The importance of an optimal time in therapeutic range (TTR) was emphasised in this trial. A total of 2,800 patients with AF without dementia were enrolled. Incident dementia was diagnosed in 357 patients (12.8%) over a mean follow-up of 5 years. After adjusting for confounders, warfarin therapy was associated with a reduced incidence of dementia (hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.64–0.99). However, only those in the two highest quartiles of TTR were associated with a lower risk of dementia. The importance of TTR for a positive effect of anticoagulation with vitamin K antagonists was also reported in two other studies.58,59

A systematic review of 19 studies analysed the association between cognitive impairment and anticoagulation.60 The pooled odds ratio (OR) suggested no association with incident dementia, when comparing anticoagulation with antiplatelet therapy (two studies, OR 1.23; 95% CI 0.80–1.91) or no treatment (three studies, OR 0.89; 95% CI 0.47–1.69). Thus, this review did not show definitive evidence of cognitive benefit or harm from anticoagulation. Direct oral anticoagulants (DOACs) have also been evaluated with regards to their impact on new-onset dementia and compared with warfarin. In a propensity-matched analysis, the risk of developing stroke, transient ischaemic attack or dementia was 43% lower in patients treated with DOACs compared to warfarin. But this difference was not statistically significant (HR 0.57; 95% CI 0.17–1.97; p=0.38).61

A Swedish retrospective registry study between 2006 and 2014 including 444,106 patients with AF with no previous diagnosis of dementia investigated the possible effect of anticoagulation on the incidence of dementia.62 Propensity score matching, falsification endpoints, intention-to-treat, and on-treatment analyses were used. Patients without prior stroke and on anticoagulation treatment had a 29% lower risk of dementia than patients without anticoagulation (HR 0.71; 95% CI 0.68–074). Comparison between DOACs and warfarin showed no significant difference.

In a Danish nationwide cohort study including 33,617 patients with AF with a mean follow-up of 3.4 years, no clinically meaningful difference in dementia development between users of DOACs and warfarin was found.63 Relative to warfarin users, dementia rates were non-significantly lower among DOAC users aged 60–69 years (HR 0.92; 95% CI 0.48–1.72) and DOAC users aged 70–79 years (HR 0.86; 95% CI 0.68–1.09), whereas DOACs were associated with significantly higher dementia rates in patients aged ≥80 (HR 1.31; 95% CI 1.07–1.59). According to the authors, the latter may relate to residual confounding from selective prescribing and unobserved comorbidities.

In summary, there is indirect evidence that effective anticoagulation in patients with AF reduces the risk of cognitive impairment and dementia. Large prospective clinical trials on this subject are needed.

Rhythm control

Cardioversion, or AF ablation, may result in sinus rhythm and improve cardiac output and cerebral perfusion. The impact of these treatment options on dementia has been investigated in several studies. In the Intermountain AF study, 4,212 consecutive patients with AF who underwent AF ablation were compared with 16,848 age- and sex-matched control subjects with AF without ablation and 16,848 age- and sex-matched individuals without AF.64 Follow-up was >3 years and Alzheimer’s disease occurred 0.2% of the patients who underwent AF ablation, 0.9% of the patients with AF but no ablation and in 0.5% of the patients without AF (p<0.0001). Other forms of dementia also appear to be significantly reduced by AF ablation; in a recent study, the risk of dementia and hospitalisation was studied in 787 patients with AF who received catheter ablation, and their propensity scores were matched to 787 patients with AF not receiving ablation, and 770 patients without AF. Over 9.0 (± 2.6) years of follow-up, 139 dementia events and 732 AF-related hospitalisations occurred. In those patients with AF who underwent ablation, the incidence of dementia was lower than in the group without ablation (adjusted HR 0.44, p=0.005). AF-related hospitalisations were also lower in the ablation group (adjusted HR 0.72, p<0.05). The reduction of dementia risk was especially clear in older patients aged >65 years with AF ablation, compared to those without AF ablation (adjusted HR 0.46, p=0.03).65 According to the MACPAF (Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation) study, AF burden had no significant impact on cognitive performance 6 months after AF ablation.66

Further ongoing clinical trials on the association between AF, cognitive impairment, cognitive decline, and dementia are summarised in Table 4.


AF can be regarded as an independent cardiovascular risk factor for the development of cognitive decline and dementia. Several recent studies suggest an association between AF, cognitive impairment, cognitive decline, and dementia, in those both with and without a history of stroke. AF increases the risk of vascular dementia as well as Alzheimer’s disease. Both types of dementia and AF share the same risk factors, including hypertension, heart failure, diabetes, dyslipidaemia, age, obesity and physical inactivity. These risk factors, alone or in combination, can lead to silent strokes and microbleeds, as well as chronic cerebral hypoperfusion, which are more common in patients with AF than in patients in sinus rhythm. The association between AF and dementia is strongest in patients <65 years of age.

Anticoagulation, either with vitamin K antagonists or DOACs, has been proven to be effective in preventing strokes in AF and there is emerging evidence that anticoagulation in patients with AF could also be effective to reduce cognitive decline even in those without a history of stroke. This, however, still needs to be proven in ongoing and future clinical trials.

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchcardio is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.